secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2023-02-01T23:59:59+00:00
Accession:  0001193125-23-021525
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen updates INTERCEPT-AD trial enrollment, dose reduction for Cohort 7
-------------------------------------------------------------------------

- Expects enrollment completion Q1 2023, topline data Q3 2023.
- 52 subjects randomized and dosed in Cohorts 1-6 as of Jan 31, 2023.
- Submitted protocol amendment Jan 30, 2023: Cohort 7 reduced to 25 mg/kg every 2 weeks from 60 mg/kg.
- Two asymptomatic ARIA-E cases: one in Cohort 4 (single 60 mg/kg), one in Cohort 5 (third 10 mg/kg).
- Dose reduction based on blinded PK/PD data; 60 mg/kg every 2 weeks deemed unnecessary for target engagement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000119312523021525/0001193125-23-021525-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000119312523021525/d453609d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-021525

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer